06:57 AM EDT, 09/25/2024 (MT Newswires) -- 2seventy bio (TSVT) said Wednesday it would discontinue enrollment for the ongoing phase 3 study of Abecma with lenalidomide maintenance as treatment for newly diagnosed multiple myeloma due to scarce eligible patients for the trial.

Shares of the company were down 7.3% in recent premarket activity.

Treatments for NDMM have "improved considerably" since the study was launched, and as a result, "there are considerably fewer eligible patients than when the study was first designed," 2seventy said.

2seventy and Abecma partner Bristol Myers Squibb ( BMY ) plan to continue studying the drug among multiple myeloma patients.

2seventy expects to save over $80 million in the following years from the discontinuation.

Price: 4.4200, Change: -0.35, Percent Change: -7.34